Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas Jimenez, Marc
  • Masia Fandos, Nuria
  • Suarez Cabrera, Leticia
  • Olivan Riera, Mireia
  • Soriano Fernández, Aroa
  • Majem Cavaller, Blanca
  • Jimenez Jimenez, Carlos Gonzalo
  • Boloix Amenós, Ariadna
  • Toledano Martin, Ignasi
  • Navarro Jimenez, Alexandra
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Santamaria Margalef, Anna
  • Guillén Burrieza, Gabriela
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review

  • Bradbury Lobato, Melissa
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Teixit cancerígen; Càncer d'ovaris; Proteòmica, Tejido canceroso; Cáncer de ovarios; Proteómica, Cancer tissue; Ovarian cancer; Proteomics, High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science and Innovation (CTQ2016-80364-P) and “Centro de Excelencia Severo Ochoa 2013–2017”, SEV-2012-0208; the “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661), from the Instituto de Salud Carlos III (PI15/02238, PI18/01017, CPII18/00027) and from the Ministerio de Economia y Competitividad y Fondos FEDER (RTC-2015-3821). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury Lobato, Melissa
  • Castellví Vives, Josep
  • Mendez Fernández, Olga
  • Sánchez Iglesias, José Luis
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Ovarian cancer; Proteomics, Cáncer de ovarios: Proteómica, Càncer d'ovaris; Proteòmica, Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, (CTQ2016-80364-P and “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208), and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). It has also been supported by grants from the Instituto Carlos III (PI15/00238, PI18/01017, PI21/00977), the Miguel Servet Program (CP13/00158 and CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1). The authors are grateful to the team members of the Proteomics Unit at the Centre for Genomic Regulation, the Biomedical Research Group in Gynecology at the Vall d’Hebron Institute, the Gynecological Oncology Unit at the Vall d’Hebron Hospital and the Biomedical Research Group in Urology at the Vall d’Hebron Institute for their assistance.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan Riera, Mireia
  • Garcia Lopez, Marta
  • Suarez Cabrera, Leticia
  • Guiu, Marc
  • Gros, Laura
  • Mendez Fernández, Olga
  • Segura Ginard, Miguel
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Morote Robles, Joan
  • De la Cruz Montserrat, Fco. Xavier
  • Santamaria Margalef, Anna
Bone metastasis; MiRNAs; Prostate cancer, Metàstasi òssia; MiRNAs; Càncer de pròstata, Metástasis ósea; MiRNAs; Cáncer de próstata, About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients’ quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells’ migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b’s role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa., The study was supported by grants CPII18/00027 and PI18/01017 to A.S.; PI17/02248 to J.M.; grants PI09/00496, PI13/00173 and postdoctoral fellowship CD12/00475 of Instituto de Salud Carlos III (ISCIII), pre-doctoral fellowship of Vall d’Hebron Research Institute (VHIR), postdoctoral fellowship PERIS of Departament de Salut Govern de Catalunya to M.O.; BBVA and PID2019-104948RB-100 to M.G. (Marc Guiu) and R.R.G.; RD12/0036/0035 of Red Temática de investigación cooperativa en cancer (RTICC), and 2014SGR1330 from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya”.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer

  • Parrilla, Alfonso
  • Barber, Marta
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Castellvi, Josep|||0000-0001-5745-9996
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Sánchez Iglesias, José Luis|||0000-0002-4542-3969
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Identifying novel actionable factors that critically contribute to tumorigenesis is essential in ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options available. Here we show that Aurora Borealis (BORA), a mitotic protein that plays a key role in activating the master mitotic kinase polo-like kinase 1 (PLK1), has an oncogenic role in ovarian cancer. Gain and loss of function assays on mouse models and ex vivo patient-derived ascites cultures revealed an oncogenic role of BORA in tumor development and a transcriptome-analysis in clinically representative models depicted BORA's role in survival, dissemination and inflammatory cancer related-pathways. Importantly, combinatory treatments of FDA-approved inhibitors against oncogenic downstream effectors of BORA displayed synergistic effect in ovarian cancer models, offering promising therapeutic value. Altogether, our findings uncovered for the first time a critical role of BORA in the viability of human cancer cells providing potential novel therapeutic opportunities for ovarian cancer management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients, A Mini-Review

  • Bradbury, Melissa|||0000-0003-4974-8899
  • Borràs, Eva|||0000-0002-3859-9907
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Sabidó, Eduard|||0000-0001-6506-7714
In this manuscript, we review the management strategies available for high-grade serous ovarian cancer patients and the molecular advances that are helping improve our understanding of the tumor and its response to treatment. We emphasize the role that proteomics is now playing in the study of ovarian cancer tumors and how its integration with genomics can guide the development of new biomarkers and therapeutic targets. High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Hümmer, Stefan|||0000-0002-8184-3872
  • Masanas, Marc|||0000-0002-2249-8554
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Guitart, Maria|||0000-0003-2957-7404
  • Jeyaprakash, A. Arockia
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Ruiz, Anna|||0000-0001-7314-5962
KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. Here, we report a patient presenting a severe neurodevelopmental disorder carrying a novel de novo missense variant p.Arg169Thr (R169T) in the KIF1A motor domain. The clinical features present in our patient match with those reported for NESCAV syndrome including severe developmental delay, spastic paraparesis, motor sensory neuropathy, bilateral optic nerve atrophy, progressive cerebellar atrophy, epilepsy, ataxia, and hypotonia. Here, we demonstrate that the microtubule-stimulated ATPase activity of the KIF1A is strongly reduced in the motor domain of the R169T variant. Supporting this, in silico structural modeling suggests that this variant impairs the interaction of the KIF1A motor domain with microtubules. The characterization of the molecular effect of the R169T variant on the KIF1A protein together with the presence of the typical clinical features indicates its causal pathogenic effect.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan Riera, Mireia
  • Garcia Lopez, Marta
  • Suarez Cabrera, Leticia
  • Guiu, Marc
  • Gros, Laura
  • Mendez Fernández, Olga
  • Segura Ginard, Miguel
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Morote Robles, Joan
  • De la Cruz Montserrat, Fco. Xavier
  • Santamaria Margalef, Anna
Bone metastasis; MiRNAs; Prostate cancer, Metàstasi òssia; MiRNAs; Càncer de pròstata, Metástasis ósea; MiRNAs; Cáncer de próstata, About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients’ quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells’ migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b’s role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa., The study was supported by grants CPII18/00027 and PI18/01017 to A.S.; PI17/02248 to J.M.; grants PI09/00496, PI13/00173 and postdoctoral fellowship CD12/00475 of Instituto de Salud Carlos III (ISCIII), pre-doctoral fellowship of Vall d’Hebron Research Institute (VHIR), postdoctoral fellowship PERIS of Departament de Salut Govern de Catalunya to M.O.; BBVA and PID2019-104948RB-100 to M.G. (Marc Guiu) and R.R.G.; RD12/0036/0035 of Red Temática de investigación cooperativa en cancer (RTICC), and 2014SGR1330 from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya”.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury Lobato, Melissa
  • Castellví Vives, Josep
  • Mendez Fernández, Olga
  • Sánchez Iglesias, José Luis
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Ovarian cancer; Proteomics, Cáncer de ovarios: Proteómica, Càncer d'ovaris; Proteòmica, Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, (CTQ2016-80364-P and “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208), and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). It has also been supported by grants from the Instituto Carlos III (PI15/00238, PI18/01017, PI21/00977), the Miguel Servet Program (CP13/00158 and CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1). The authors are grateful to the team members of the Proteomics Unit at the Centre for Genomic Regulation, the Biomedical Research Group in Gynecology at the Vall d’Hebron Institute, the Gynecological Oncology Unit at the Vall d’Hebron Hospital and the Biomedical Research Group in Urology at the Vall d’Hebron Institute for their assistance.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review

  • Bradbury Lobato, Melissa
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Teixit cancerígen; Càncer d'ovaris; Proteòmica, Tejido canceroso; Cáncer de ovarios; Proteómica, Cancer tissue; Ovarian cancer; Proteomics, High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science and Innovation (CTQ2016-80364-P) and “Centro de Excelencia Severo Ochoa 2013–2017”, SEV-2012-0208; the “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661), from the Instituto de Salud Carlos III (PI15/02238, PI18/01017, CPII18/00027) and from the Ministerio de Economia y Competitividad y Fondos FEDER (RTC-2015-3821). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas Jimenez, Marc
  • Masia Fandos, Nuria
  • Suarez Cabrera, Leticia
  • Olivan Riera, Mireia
  • Soriano Fernández, Aroa
  • Majem Cavaller, Blanca
  • Jimenez Jimenez, Carlos Gonzalo
  • Boloix Amenós, Ariadna
  • Toledano Martin, Ignasi
  • Navarro Jimenez, Alexandra
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Santamaria Margalef, Anna
  • Guillén Burrieza, Gabriela
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).